TriangleNCT01614821 · OUTCOME
Determine Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- 6 years
What was measured
To determine Progression Free Survival (PFS in symptomatic WM patients with relapsed/refractory disease. Participants were treated for 40 cycles and then followed for 2 years or until next therapy or death. 40 participants were censored prior to disease progression.
Groups in this outcome
Treatment Arm
PCI-32765; ibrutinib PCI-32765: Taken orally, once daily in the morning
| Group | Source count |
|---|---|
| Treatment Arm | 63 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment Arm | 39 | Not reported | 0 | 67 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 67
- value
- 39
- denoms
- counts
- group Id
- OG000
- value
- 63
- units
- Participants
- description
- To determine Progression Free Survival (PFS in symptomatic WM patients with relapsed/refractory disease. Participants were treated for 40 cycles and then followed for 2 years or until next therapy or death. 40 participants were censored prior to disease progression.
- dispersion Type
- Full Range
- groups
- description
- PCI-32765; ibrutinib PCI-32765: Taken orally, once daily in the morning
- id
- OG000
- title
- Treatment Arm
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 6 years
- title
- Determine Progression Free Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice